#hemodialysis 2020

[marketanalysisdata]

Continuous Renal Replacement Therapy Market 2030 - In-Depth Analysis on Size, Trends & Prominent Key Players

The global continuous renal replacement therapy market was valued at USD 1,356.7 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. Factors contributing to this growth include the rising incidence of acute kidney injury (AKI), an increase in sepsis cases, the rapid expansion of hospitals and urgent care centers, growing hospital admission rates, and continuous product innovations by leading companies. The American Kidney Fund reports that 37 million Americans are living with kidney disease, and around 807,000 individuals in the U.S. have been diagnosed with kidney failure.

Demand for advanced CRRT devices is a major driver in the market due to improved patient outcomes. The latest CRRT technology allows for comprehensive analysis and response to technical data, significantly enhancing quality assurance. These technological advancements have led to a more precise evaluation of prescription and delivery patterns, positively impacting clinical results. Modern CRRT devices enable automated data collection and use standardized language, facilitating comparisons across institutions. Leading manufacturers have introduced sophisticated CRRT machines incorporating these capabilities, which is expected to further accelerate market growth.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Additionally, the development of specialized CRRT products for pediatric patients is anticipated to boost the market. Traditionally, pediatric CRRT cases have relied on systems designed for adults, which are not specifically licensed for pediatric use, posing potential clinical challenges, especially for neonates. To address these issues, several manufacturers now provide a range of renal care solutions to improve access, outcomes, and quality of life for pediatric patients with severe renal conditions, driving market expansion globally.

According to the American Hospital Association, in 2023, the U.S. had 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals. An increase in hospital admissions for AKI and a growing elderly population are fueling the demand for CRRT systems. Moreover, the Centers for Disease Control and Prevention (CDC) reported that, as of 2021, approximately 786,000 Americans had end-stage renal disease (ESRD), also known as end-stage kidney disease (ESKD), with 71% on dialysis and 29% with a kidney transplant. In 2020, there were around 7,500 dialysis clinics in the U.S., underscoring the need for CRRT solutions.

Modality Segmentation Insights:

The CRRT market can be segmented into different modalities: slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). In 2022, the CVVH segment led the market with a revenue share of 31.6%, driven by the high prevalence of fluid overload among AKI patients in critical care settings. Fluid overload, often seen in congestive heart failure cases, significantly impacts dialysis patients. According to an article in Elsevier, congestive heart failure accounted for roughly 5% of all-cause mortality among dialysis patients, a condition closely related to fluid overload. This association is expected to increase demand for CVVH treatment.

The CVVHDF segment is anticipated to grow at the fastest CAGR of 9.2% over the forecast period. CVVHDF, which utilizes a highly effective hemodiafilter, enables the combined removal of fluid and solutes, merging both hemodialysis and hemofiltration techniques. This treatment involves comprehensive fluid and solute clearance from the blood and has become the most commonly used CRRT modality for AKI in various countries. CVVH was the primary CRRT modality until CVVHDF was introduced in 2008, which quickly became the dominant CRRT approach. CVVHDF’s association with higher survival rates relative to other CRRT options is expected to contribute to its rapid market growth in the coming years.

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.

[marketstudyreport]

Continuous Renal Replacement Therapy Market Comprehensive Analysis and Future Estimations by 2030

The global continuous renal replacement therapy market was valued at USD 1,356.7 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. Factors contributing to this growth include the rising incidence of acute kidney injury (AKI), an increase in sepsis cases, the rapid expansion of hospitals and urgent care centers, growing hospital admission rates, and continuous product innovations by leading companies. The American Kidney Fund reports that 37 million Americans are living with kidney disease, and around 807,000 individuals in the U.S. have been diagnosed with kidney failure.

Demand for advanced CRRT devices is a major driver in the market due to improved patient outcomes. The latest CRRT technology allows for comprehensive analysis and response to technical data, significantly enhancing quality assurance. These technological advancements have led to a more precise evaluation of prescription and delivery patterns, positively impacting clinical results. Modern CRRT devices enable automated data collection and use standardized language, facilitating comparisons across institutions. Leading manufacturers have introduced sophisticated CRRT machines incorporating these capabilities, which is expected to further accelerate market growth.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Additionally, the development of specialized CRRT products for pediatric patients is anticipated to boost the market. Traditionally, pediatric CRRT cases have relied on systems designed for adults, which are not specifically licensed for pediatric use, posing potential clinical challenges, especially for neonates. To address these issues, several manufacturers now provide a range of renal care solutions to improve access, outcomes, and quality of life for pediatric patients with severe renal conditions, driving market expansion globally.

According to the American Hospital Association, in 2023, the U.S. had 5,157 community hospitals, 206 federal government hospitals, and 107 other hospitals. An increase in hospital admissions for AKI and a growing elderly population are fueling the demand for CRRT systems. Moreover, the Centers for Disease Control and Prevention (CDC) reported that, as of 2021, approximately 786,000 Americans had end-stage renal disease (ESRD), also known as end-stage kidney disease (ESKD), with 71% on dialysis and 29% with a kidney transplant. In 2020, there were around 7,500 dialysis clinics in the U.S., underscoring the need for CRRT solutions.

Modality Segmentation Insights:

The CRRT market can be segmented into different modalities: slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), and continuous venovenous hemodiafiltration (CVVHDF). In 2022, the CVVH segment led the market with a revenue share of 31.6%, driven by the high prevalence of fluid overload among AKI patients in critical care settings. Fluid overload, often seen in congestive heart failure cases, significantly impacts dialysis patients. According to an article in Elsevier, congestive heart failure accounted for roughly 5% of all-cause mortality among dialysis patients, a condition closely related to fluid overload. This association is expected to increase demand for CVVH treatment.

The CVVHDF segment is anticipated to grow at the fastest CAGR of 9.2% over the forecast period. CVVHDF, which utilizes a highly effective hemodiafilter, enables the combined removal of fluid and solutes, merging both hemodialysis and hemofiltration techniques. This treatment involves comprehensive fluid and solute clearance from the blood and has become the most commonly used CRRT modality for AKI in various countries. CVVH was the primary CRRT modality until CVVHDF was introduced in 2008, which quickly became the dominant CRRT approach. CVVHDF’s association with higher survival rates relative to other CRRT options is expected to contribute to its rapid market growth in the coming years.

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.

[deshpandeisha]

Introduction to Continuous Renal Replacement Therapy (CRRT)

The global continuous renal replacement therapy (CRRT) market size was USD 1.41 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.8% during the forecast period. The continuous renal replacement therapy (CRRT) market is a rapidly growing sector of the medical industry. CRRT is a process used to treat patients with acute kidney injury (AKI) or chronic kidney disease (CKD) by removing waste products and excess fluids from the blood. The therapy is continuous and performed over an extended period of time, providing a gentler and more effective treatment option than traditional dialysis. According to the National Kidney Foundation, CKD affects an estimated 37 million people in the United States, and AKI affects up to 20% of hospitalized patients.

One of the key drivers of the CRRT market is the increasing prevalence of kidney diseases. The National Kidney Foundation estimates that approximately 90% of people with kidney disease are unaware they have it. This lack of awareness means that many people may not receive proper treatment until their kidney function has already declined significantly. As a result, the demand for effective treatments like CRRT is expected to increase as more people are diagnosed with kidney diseases.

However, there are also some restraints that could hinder the growth of the CRRT market. One major restraint is the high cost of the therapy. CRRT is a complex and expensive process that requires specialized equipment and highly trained medical professionals. This can make the therapy inaccessible to some patients who cannot afford the high cost of treatment.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample/1856

The leading market contenders listed in the report are: Baxter International Inc., Asahi Kasei Medical Co., Ltd., Fresenius Medical Care AG & Co. KGaA, Medtronic plc, B. Braun SE, Nipro Corporation, Informed SA, Toray Medical Co. Ltd, Medical Components Inc., and Nikkiso Co., Ltd

The research study examines historic data from 2018 and 2020 to draw forecasts until 2030. The timeline makes the report an invaluable resource for readers, investors, and stakeholders looking for key insights in readily accessible documents with the information presented in the form of tables, charts, and graphs. To Visit Full Report & Table of Contents Continuous Renal Replacement Therapy Market: https://www.emergenresearch.com/industry-report/continuous-renal-replacement-therapy-market

Market Overview: The report bifurcates the Continuous Renal Replacement Therapy market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment. Segments Covered in this report are:

Product Outlook (Revenue, USD Billion; 2019-2032)

Dialysate and Replacement Fluids

Disposable

System

Modality Outlook (Revenue, USD Billion; 2019-2032)

Slow Continuous Ultra-Filtration (SCUF)

Continuous Venovenous Hemofiltration (CVVH)

Continuous Venovenous Hemodialysis (CVVHD)

Continuous Venovenous Hemodiafiltration (CVVHDF)

End-Use Outlook (Revenue, USD Billion; 2019-2032)

Hospitals and Clinics

Ambulatory Surgical Centers (ASCs)

Others

The research report offers a comprehensive regional analysis of the market with regards to production and consumption patterns, import/export, market size and share in terms of volume and value, supply and demand dynamics, and presence of prominent players in each market. Get An Impressive Discount On This Report@ https://www.emergenresearch.com/request-discount/1856

Regional Analysis Covers: North America (U.S., Canada) Europe (U.K., Italy, Germany, France, Rest of EU) Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC) Latin America (Chile, Brazil, Argentina, Rest of Latin America) Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of MEA)

Key reasons to buy the Global Continuous Renal Replacement Therapy Market report:

The latest report comprehensively studies the global Continuous Renal Replacement Therapy market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.

The report offers an insightful analysis of the regional outlook of the market.

It offers a detailed account of the end-use applications of the products & services offered by this industry.

The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.

Request Customization as per your specific requirement@ https://www.emergenresearch.com/request-for-customization/1856

[industrynewsupdates]

Continuous Renal Replacement Therapy Market Segmentation and Competitive Analysis Report, 2030

The global continuous renal replacement therapy market��size was valued at USD 1,356.7 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2023 to 2030. 

Rising incidence of acute kidney injury (AKI), increasing incidence of sepsis, rapid increase in the volume of hospitals and urgent care centers, growing hospital admissions rate, and constant product launches by prominent market players are a few factors driving the demand for CRRT, thereby propelling the market growth. According to the American Kidney Fund, 37 million U.S. citizens are living with kidney disease and 807,000 people in the U.S. are diagnosed with kidney failure.

In the pre-COVID-19 era, the burden of COVID-19-associated AKI climbed to almost 4 million cases per year. CRRT was utilized to treat roughly 23,105 AKI patients per year prior to COVID-19. The need for CRRT appeared to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, than in historical populations (0.9 percent). In community cohort datasets, 5%–15% of people hospitalized with COVID-19 needed dialysis. Moreover, in some North America regions, the number of people utilizing CRRT jumped by 370 percent over normal levels due to which the demand for the product increased during the pandemic. For instance, Fresenius Medical Care North America's Renal Therapies Group (FMCNA) released the first batch of multiBic dialysate solutions to U.S. hospitals in May 2020, according to an FDA emergency use authorization. These medicines were intended to provide CRRT to COVID-19-related individuals with acute renal failure.

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

Continuous Renal Replacement Therapy Market Report Highlights

• By product, the consumables segment held the largest revenue share of 60.6% in 2022. Although these products are low-priced, it is used repeatedly purchased; hence the market for consumables is the largest as compared to other segments

• Based on the modality, the Continuous Veno-venous Hemofiltration (CVVH) segment held the largest revenue share of 31.6% in 2022. Fluid overload situations, which are common in acute kidney injury patients in critical care units, are expected to increase, boosting the CVVH market's growth

• Asia Pacific was the fastest growing market for continuous renal replacement therapy with a growth rate of 9.8%. Various factors are responsible for the region growth such as technological advancement, growing healthcare infrastructure development as well as and presence of such a huge patient base in this region

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global sentinel node biopsy market size was estimated at USD 717.8 million in 2023 and is projected to grow at a CAGR of 7.0% from 2024 to 2030.

• The global market for endoscopy operative devices reached a value of USD 10.34 billion in 2023 and is projected to grow at a CAGR of 5.3% from 2024 to 2030. 

Continuous Renal Replacement Therapy Market Segmentation

Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:

Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)

• System

• Consumables

Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2018 - 2030)

• Slow Continuous Ultra-Filtration (SCUF)

• Continuous Venovenous Hemofiltration (CVVH)

• Continuous Venovenous Hemodialysis (CVVHD)

• Continuous Venovenous Hemodiafiltration (CVVHDF)

Continuous Renal Replacement Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o China

o Japan

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.

[24global-news]

The Cashier in Dubai

Investigative report tracks tangled route for money flowing to offshore companies from Moldova.

Part One

Moldovan oligarch Vladimir Plahotniuc left his home country in 2019 to avoid corruption charges. But an investigation into his business affairs, supported by newspress24-blog, shows that money continued to flow into his pockets long after he fled.

Black Box Plus, the investigative show of Moldova’s independent Tv channel TV8, acquired documents showing that Plahotniuc profited from every document Moldova’s Public Services Agency (ASP) issued between 2014-2019. Black Box TV followed the traces left by the businessman Alexandru Vilcu and Vladimir Andronachi, a former lawmaker with the Democratic Party (PD).

Documents show that the money reached Plahotniuc via Garsų Pasaulis, the Lithuanian printing house that won the public procurements for supplying blank cards the ASP uses to issue Moldovan documents, including passports. The financial circuit leads to a network of offshore companies registered in Cyprus, Hong Kong and the United Arab Emirates (UAE).

In the summer of 2020, the scheme Plahotniuc built over the years was taken over by two Bulgaria-registered companies that appeared overnight.

These companies were the identical financial offshore vehicles through which Plahotniuc, former leader of the PD, raised alleged dividends from the auctions organised by the state telecom company Moldtelecom, the purchase of electricity from the breakaway region of Transnistria, the public-private partnership for hemodialysis services and the so–called heist of one billion US dollars from the Moldovan banking system.

The Lithuanian UAB (an acronym of uždaroji akcine bendrove, or private limited company) started supplying blank cards for Moldovan passports following tenders in 2014 and 2017. The main beneficiary of the Garsu Pasaulis company is Albert Mario Karaziwan, a Belgian citizen who owns Semlex Europe, an identification document and biometric device production company whose business practices have come under scrutiny. The Syrian-Belgium businessman has been targeted in several countries in criminal corruption cases and journalistic investigations by Reuters and OCCRP.

In 2014, Moldova’s minister of information and communications technology was Plahotniuc’s fellow party member Pavel Filip. The CRIS Registru state enterprise which in 2017 was re-organised as ASP, was headed by Sergey Railean, godfather of Filip's older son.

Between 2014 and 2021, ASP transferred 59.5 million euros to the Garsu Pasaulis company "for raw material, blank cards and personalisation services," according to documents obtained by Black Box.

ASP also paid the Lithuanian company a royalty fee for software developed for Moldova and used on three types of documents. For example, the royalty fee for each passport issued was 13.61 euros (14.49 US dollars). On October 22, 2021, prosecutors opened a criminal case against nine people from the Public Services Agency “targeted in a criminal case of abuse of office”. Prosecutors estimated that the state lost around 41 million euros (43.6 million dollars) in the case.

A LONG AND TANGLED PATH

A note from the Moldovan service for the Prevention and Combating of Money Laundering obtained by Black Box shows that more than 24 million euros (25.54 million dollars) did not stop in the company's accounts in Vilnius but ended up in Cyprus and the UAE.

“Of the 135 payments made throughout this period [2014-2019], I can tell you that the final beneficiary is obvious. At least, from what the criminal investigation bodies say, it is clear that the actual beneficiary is Vladimir Plahotniuc,” said ASP director Mircea Esanu.

Sergey Railean, the ASP former director under whose mandate the two contracts with Garsu Pasaulis were signed, said that he knew nothing about benefits for Plahotniuc.

"The tender took place according to the procedures. Therefore, nothing was outside the law," Railean said.

Told that Black Box reporters had established money transfers from Garsu Pasaulis to offshore companies affiliated with Plahotniuc, Railean was asked if he knew anything about it.

"No, absolutely not. Now it is a criminal case. The file must be completed after the trial,"he said. “[…] We did not order any software."

Railean added that ASP paid royalty fees to Garsu Pasaulis "because that was the contract".

On May 5, 2022 the Moldovan anti-corruption prosecutor's office announced that Railean had the status of accused in the so-called passport affair.

Filip, who held the post of prime minister in 2016-2019, did not answer the phone calls or requests for comment.

In May 2018, during a TV show broadcast by Prime, one of Plahotniuc's TV stations, Filip hinted that the state signed a more advantageous contract with Garsu Pasaulis than the previous one agreed in 2011 with a French company.

In 2011, Garsu Pasaulis had in fact tried to win a tender, but its application failed as it did not meet ASP’s criteria. A key condition was that applicants had experience manufacturing electronic passports for at least three European countries, as established by a decision of the Supreme Court of Justice. Garsu Pasaulis did not meet this requirement.

Garsu Pasaulis replied via e-mail that the company won the tenders and successfully delivered blank passport cards for ASP.

“As for the exact details of other commercial contracts, we cannot provide any details as confidentiality commitments bind us,” Andrius Lukosevicius, director of Garsu Pasaulis’ printing security department, wrote. “However, we can confirm that we have never had and do not currently have commercial or other relations with Mr Plahotniuc and [Romanian businesswoman] Mrs Ileana-Mihaela Burcea.”

The passport cash headed south, to the UAE firm Prime Union Solutions FZ LLC. Between January 1, 2018 and July 30, 2019 itreceived transfers for over 4.7 million euros ( five million dollars) from Garsu Pasaulis. The money continued to flow into Plahotniuc's coffers even after he fled Moldova in June 2019 when his name was linked to the disappearance of over a billion dollars - nearly one-eighth of Moldova's GDP - from the country's biggest banks between 2012 and 2014.

Employees at the Moldovan Money Laundering Prevention and Combating Service obtained information from their colleagues in Dubai and stated that the company's majority shareholders were the Romanian citizen Ileana-Mihaela Burcea and the company Inter Gnathonize Limited.

Between October 29, 2018, and July 30, 2019, a total of seven million euros (about 7.4 million dollars) were credited into Prime Union Solutions’ UAE bank account, largely sent from Garsu Pasaulis. The money then traveled to Burcea’s private account in UAE and six other offshore companies.

In liaison with UAE and Cyprus’ authorities, Moldova’s law enforcement agencies determined that Garsu Pasaulis transferred another 19.6 million euros (20.8 million dollars) to another Cyprus offshore company, Gnathonize Limited, also connected to Burcea.

The Cypriot firm opened a bank account in July 2014, four months after Garsu Pasaulis won the Moldova tender. The Lithuanian firm was the main contributor to the account until August 2018. After that, the money was transferred to the company Prime Union INC LTD in Hong Kong and marked as a "dividend payment".

[newspress24-blog]

The Cashier in Dubai

Investigative report tracks tangled route for money flowing to offshore companies from Moldova.

Part One

Moldovan oligarch Vladimir Plahotniuc left his home country in 2019 to avoid corruption charges. But an investigation into his business affairs, supported by newspress24-blog, shows that money continued to flow into his pockets long after he fled.

Black Box Plus, the investigative show of Moldova’s independent Tv channel TV8, acquired documents showing that Plahotniuc profited from every document Moldova’s Public Services Agency (ASP) issued between 2014-2019. Black Box TV followed the traces left by the businessman Alexandru Vilcu and Vladimir Andronachi, a former lawmaker with the Democratic Party (PD).

Documents show that the money reached Plahotniuc via Garsų Pasaulis, the Lithuanian printing house that won the public procurements for supplying blank cards the ASP uses to issue Moldovan documents, including passports. The financial circuit leads to a network of offshore companies registered in Cyprus, Hong Kong and the United Arab Emirates (UAE).

In the summer of 2020, the scheme Plahotniuc built over the years was taken over by two Bulgaria-registered companies that appeared overnight.

These companies were the identical financial offshore vehicles through which Plahotniuc, former leader of the PD, raised alleged dividends from the auctions organised by the state telecom company Moldtelecom, the purchase of electricity from the breakaway region of Transnistria, the public-private partnership for hemodialysis services and the so–called heist of one billion US dollars from the Moldovan banking system.

The Lithuanian UAB (an acronym of uždaroji akcine bendrove, or private limited company) started supplying blank cards for Moldovan passports following tenders in 2014 and 2017. The main beneficiary of the Garsu Pasaulis company is Albert Mario Karaziwan, a Belgian citizen who owns Semlex Europe, an identification document and biometric device production company whose business practices have come under scrutiny. The Syrian-Belgium businessman has been targeted in several countries in criminal corruption cases and journalistic investigations by Reuters and OCCRP.

In 2014, Moldova’s minister of information and communications technology was Plahotniuc’s fellow party member Pavel Filip. The CRIS Registru state enterprise which in 2017 was re-organised as ASP, was headed by Sergey Railean, godfather of Filip's older son.

Between 2014 and 2021, ASP transferred 59.5 million euros to the Garsu Pasaulis company "for raw material, blank cards and personalisation services," according to documents obtained by Black Box.

ASP also paid the Lithuanian company a royalty fee for software developed for Moldova and used on three types of documents. For example, the royalty fee for each passport issued was 13.61 euros (14.49 US dollars). On October 22, 2021, prosecutors opened a criminal case against nine people from the Public Services Agency “targeted in a criminal case of abuse of office”. Prosecutors estimated that the state lost around 41 million euros (43.6 million dollars) in the case.

A LONG AND TANGLED PATH

A note from the Moldovan service for the Prevention and Combating of Money Laundering obtained by Black Box shows that more than 24 million euros (25.54 million dollars) did not stop in the company's accounts in Vilnius but ended up in Cyprus and the UAE.

“Of the 135 payments made throughout this period [2014-2019], I can tell you that the final beneficiary is obvious. At least, from what the criminal investigation bodies say, it is clear that the actual beneficiary is Vladimir Plahotniuc,” said ASP director Mircea Esanu.

Sergey Railean, the ASP former director under whose mandate the two contracts with Garsu Pasaulis were signed, said that he knew nothing about benefits for Plahotniuc.

"The tender took place according to the procedures. Therefore, nothing was outside the law," Railean said.

Told that Black Box reporters had established money transfers from Garsu Pasaulis to offshore companies affiliated with Plahotniuc, Railean was asked if he knew anything about it.

"No, absolutely not. Now it is a criminal case. The file must be completed after the trial,"he said. “[…] We did not order any software."

Railean added that ASP paid royalty fees to Garsu Pasaulis "because that was the contract".

On May 5, 2022 the Moldovan anti-corruption prosecutor's office announced that Railean had the status of accused in the so-called passport affair.

Filip, who held the post of prime minister in 2016-2019, did not answer the phone calls or requests for comment.

In May 2018, during a TV show broadcast by Prime, one of Plahotniuc's TV stations, Filip hinted that the state signed a more advantageous contract with Garsu Pasaulis than the previous one agreed in 2011 with a French company.

In 2011, Garsu Pasaulis had in fact tried to win a tender, but its application failed as it did not meet ASP’s criteria. A key condition was that applicants had experience manufacturing electronic passports for at least three European countries, as established by a decision of the Supreme Court of Justice. Garsu Pasaulis did not meet this requirement.

Garsu Pasaulis replied via e-mail that the company won the tenders and successfully delivered blank passport cards for ASP.

“As for the exact details of other commercial contracts, we cannot provide any details as confidentiality commitments bind us,” Andrius Lukosevicius, director of Garsu Pasaulis’ printing security department, wrote. “However, we can confirm that we have never had and do not currently have commercial or other relations with Mr Plahotniuc and [Romanian businesswoman] Mrs Ileana-Mihaela Burcea.”

The passport cash headed south, to the UAE firm Prime Union Solutions FZ LLC. Between January 1, 2018 and July 30, 2019 itreceived transfers for over 4.7 million euros ( five million dollars) from Garsu Pasaulis. The money continued to flow into Plahotniuc's coffers even after he fled Moldova in June 2019 when his name was linked to the disappearance of over a billion dollars - nearly one-eighth of Moldova's GDP - from the country's biggest banks between 2012 and 2014.

Employees at the Moldovan Money Laundering Prevention and Combating Service obtained information from their colleagues in Dubai and stated that the company's majority shareholders were the Romanian citizen Ileana-Mihaela Burcea and the company Inter Gnathonize Limited.

Between October 29, 2018, and July 30, 2019, a total of seven million euros (about 7.4 million dollars) were credited into Prime Union Solutions’ UAE bank account, largely sent from Garsu Pasaulis. The money then traveled to Burcea’s private account in UAE and six other offshore companies.

In liaison with UAE and Cyprus’ authorities, Moldova’s law enforcement agencies determined that Garsu Pasaulis transferred another 19.6 million euros (20.8 million dollars) to another Cyprus offshore company, Gnathonize Limited, also connected to Burcea.

The Cypriot firm opened a bank account in July 2014, four months after Garsu Pasaulis won the Moldova tender. The Lithuanian firm was the main contributor to the account until August 2018. After that, the money was transferred to the company Prime Union INC LTD in Hong Kong and marked as a "dividend payment".

Part Two

Documents from the Hong Kong public registry show that Burcea was one of Prime Union’s shareholders and in 2014-2019 the director. In 2020, Burcea requested the closing of the company. In 2018, over 600,000 euros (639,000 dollars) were transferred from one of Prime Union’s bank accounts to another offshore in Gibraltar.

In addition, 1.5 million euros (1.6 million dollars) arrived in Burcea`s personal account in the UAE and almost 800,000 euros (852,600 dollars) were directed to Recon Business Data Service, a company registered in Dubai led by Burcea. The company was closed in December 2019.

Burcea’s lawyer Cristina Savulescu declined to comment on the financial transfers from Garsu Pasaulis to her client. She also did not comment on Burcea’s connection with Plahotniuc. Savulescu said that any association of her client with an alleged criminal case was damaging to her client's image.

"The judicial procedure in any criminal case, from the time of notification to the competent bodies until the time of sending a particular person to court, is non-public and confidential, meaning that third parties cannot know the content of the carried-out procedures," Savulescu said.

Documents obtained by Black Box with the support of the OCCRP network of investigative journalists show that Plahotniuc used the same infrastructure of offshore companies to take yet more funds out of Moldova.

The former politician used the offshore network for the money obtained from other auctions organised by state enterprises including Moldtelecom, Moldova’s largest telecommunication operator, gas supplier Energocom and the health ministry for dialysis-related services.

The UAE’s Recon Business Data Services, connected to Burcea, was also involved in the financial circuit of money leaked by Plahotniuc from another scheme related to Moldtelecom, concerning public tenders won by Bass Systems SRL in PD`s ruling period.

Between March 2017 to January 2019 the Chisinau-based IT company delivered technical equipment and services for Moldtelecom worth about 41 million euros (43.6 million dollars). Out of this amount, eight million euros (8.5 million dollars) and six million dollars followed the same route to the UAE through Recon Business Data Services.

OFFSHORE ACCOUNTS

Another document obtained from the Moldovan service for the Prevention and Combating of Money Laundering shows that the Dubai-based company made several transactions to two offshores used by Plahotniuc: the UAE-based Vanguard International LTD and Vanguard International Group, registered in Samoa.

Both companies appeared in Plahotniuc's wealth statements in 2018. However, in the document submitted to Moldova’s Central Electoral Commission on the eve of the February 24, 2019 parliamentary elections, the oligarch declared 4.5 million euros (4.78 million dollars), over 11 million lei (around 585,000 dollars) and 347,000 dollars as dividends obtained from the Dubai-based Vanguard International Ltd.

Moldovan prosecutors established the origin of the money collected by Plahotniuc as "dividends".

Vanguard International LTD received 8.2 million euros (8.72 million dollars) and 2.5 million dollars from UAE-registered RECON SPC LIMITED from December 2017 to May 2019.

Burcea and another Romanian citizen, Silviu Tutuianu, were behind the company in different periods. Almost the entire amount came from the other similarly named firm, the Dubai-based Recon Business Data Service.

Plahotniuc also collected "dividends" worth 1.7 million euros (1.80 million dollars) and almost 350,000 US dollars through another offshore company, TGME INVESTMENTS SPC LTD, managed by Tutuianu.

All these companies were liquidated between the end of 2019 and the beginning of 2020, after Plahotniuc fled Moldova. The Moldovan anti-corruption prosecutor's office opened a case for the purchase of equipment and services by Moldtelecom from SRL Bass Systems. The prosecutors confirmed that Burcea was interviewed in this criminal case, but did not disclose her status.

Burcea also managed a company that benefited from transfers from Plahotniuc’s Cyprus-registered Asia Pacific Textile Limited. This had transactions with the Cypriot offshore Melopmania Limited, the founder of BB-Dializa, a company which managed the dialysis services for the Moldovan health ministry.

BB Dializa also benefited from legal services from Cyprus-registered Kinanis offshore, founded by Burcea. The company also provided secretarial and legal services for Assentis Holdings Limited, one of the founders of Bass Systems SRL.

Asia Pacific Textile LTD received money from the Energokapital shell company. Between 2014 and 2016, the firm was used by Plahotniuc and Evgheni Shevciuk, former leader of Moldova’s breakaway region of Transnistria, to sell the electricity produced by the Russian-owned Moldgres Power Plant to Moldovan consumers.

The Black Box team tracked Energokapital's connections with Plahotniuc and the involvement of former DP deputy Vladimir Andronachi in the company's management.

Moldova’s service for the Prevention and Combating of Money Laundering established the connection between Burcea and two other offshore companies involved in looting a billion dollars from the country’s banking system: Sharp Prospects Limited and Lazomar Trading Limited, registered in Hong Kong and Cyprus respectively.

According to an international independent financial audit named the Kroll report, the Lazomar company received 5.6 million dollars in transfers to a Cypriot bank account. The Kroll report was commissioned by the National Bank of Moldova to investigate the theft that ravaged the country’s banking system.

Plahotniuc did not respond to requests for comment. His lawyer Lucian Rogac said that the former politician pleaded not guilty in the case generically called "blank passport cards".

"An indictment was presented to us. Other evidence to prove guilt was not shown by the prosecution. The only comment I can give you is that my client pleads not guilty to the charges," Rogac said.

In September 2022 Plahotniuc received an arrest warrant in absentia regarding the "blank passport cards" case, alongside Vladislav Zara, former director of the civil registry ASP, ex-PD deputy Andronachi and businessman Alexandru Vilcu. All of them have fled the country. According to Moldova’s ministry of justice, Plahotniuc is currently in Northern Cyprus.

[rmlnewstimes]

The Cashier in Dubai

Investigative report tracks tangled route for money flowing to offshore companies from Moldova.

Part One

Moldovan oligarch Vladimir Plahotniuc left his home country in 2019 to avoid corruption charges. But an investigation into his business affairs, shows that money continued to flow into his pockets long after he fled.

Black Box Plus, the investigative show of Moldova’s independent Tv channel TV8, acquired documents showing that Plahotniuc profited from every document Moldova’s Public Services Agency (ASP) issued between 2014-2019. Black Box TV followed the traces left by the businessman Alexandru Vilcu and Vladimir Andronachi, a former lawmaker with the Democratic Party (PD).

Documents show that the money reached Plahotniuc via Garsų Pasaulis, the Lithuanian printing house that won the public procurements for supplying blank cards the ASP uses to issue Moldovan documents, including passports. The financial circuit leads to a network of offshore companies registered in Cyprus, Hong Kong and the United Arab Emirates (UAE).

In the summer of 2020, the scheme Plahotniuc built over the years was taken over by two Bulgaria-registered companies that appeared overnight.

These companies were the identical financial offshore vehicles through which Plahotniuc, former leader of the PD, raised alleged dividends from the auctions organised by the state telecom company Moldtelecom, the purchase of electricity from the breakaway region of Transnistria, the public-private partnership for hemodialysis services and the so–called heist of one billion US dollars from the Moldovan banking system.

The Lithuanian UAB (an acronym of uždaroji akcine bendrove, or private limited company) started supplying blank cards for Moldovan passports following tenders in 2014 and 2017. The main beneficiary of the Garsu Pasaulis company is Albert Mario Karaziwan, a Belgian citizen who owns Semlex Europe, an identification document and biometric device production company whose business practices have come under scrutiny. The Syrian-Belgium businessman has been targeted in several countries in criminal corruption cases and journalistic investigations by Reuters and OCCRP.

In 2014, Moldova’s minister of information and communications technology was Plahotniuc’s fellow party member Pavel Filip. The CRIS Registru state enterprise which in 2017 was re-organised as ASP, was headed by Sergey Railean, godfather of Filip's older son.

Between 2014 and 2021, ASP transferred 59.5 million euros to the Garsu Pasaulis company "for raw material, blank cards and personalisation services," according to documents obtained by Black Box.

ASP also paid the Lithuanian company a royalty fee for software developed for Moldova and used on three types of documents. For example, the royalty fee for each passport issued was 13.61 euros (14.49 US dollars). On October 22, 2021, prosecutors opened a criminal case against nine people from the Public Services Agency “targeted in a criminal case of abuse of office”. Prosecutors estimated that the state lost around 41 million euros (43.6 million dollars) in the case.

A LONG AND TANGLED PATH

A note from the Moldovan service for the Prevention and Combating of Money Laundering obtained by Black Box shows that more than 24 million euros (25.54 million dollars) did not stop in the company's accounts in Vilnius but ended up in Cyprus and the UAE.

“Of the 135 payments made throughout this period [2014-2019], I can tell you that the final beneficiary is obvious. At least, from what the criminal investigation bodies say, it is clear that the actual beneficiary is Vladimir Plahotniuc,” said ASP director Mircea Esanu.

Sergey Railean, the ASP former director under whose mandate the two contracts with Garsu Pasaulis were signed, said that he knew nothing about benefits for Plahotniuc.

"The tender took place according to the procedures. Therefore, nothing was outside the law," Railean said.

Told that Black Box reporters had established money transfers from Garsu Pasaulis to offshore companies affiliated with Plahotniuc, Railean was asked if he knew anything about it.

"No, absolutely not. Now it is a criminal case. The file must be completed after the trial,"he said. “[…] We did not order any software."

Railean added that ASP paid royalty fees to Garsu Pasaulis "because that was the contract".

On May 5, 2022 the Moldovan anti-corruption prosecutor's office announced that Railean had the status of accused in the so-called passport affair.

Filip, who held the post of prime minister in 2016-2019, did not answer the phone calls or requests for comment.

In May 2018, during a TV show broadcast by Prime, one of Plahotniuc's TV stations, Filip hinted that the state signed a more advantageous contract with Garsu Pasaulis than the previous one agreed in 2011 with a French company.

In 2011, Garsu Pasaulis had in fact tried to win a tender, but its application failed as it did not meet ASP’s criteria. A key condition was that applicants had experience manufacturing electronic passports for at least three European countries, as established by a decision of the Supreme Court of Justice. Garsu Pasaulis did not meet this requirement.

Garsu Pasaulis replied via e-mail that the company won the tenders and successfully delivered blank passport cards for ASP.

“As for the exact details of other commercial contracts, we cannot provide any details as confidentiality commitments bind us,” Andrius Lukosevicius, director of Garsu Pasaulis’ printing security department, wrote. “However, we can confirm that we have never had and do not currently have commercial or other relations with Mr Plahotniuc and [Romanian businesswoman] Mrs Ileana-Mihaela Burcea.”

The passport cash headed south, to the UAE firm Prime Union Solutions FZ LLC. Between January 1, 2018 and July 30, 2019 itreceived transfers for over 4.7 million euros ( five million dollars) from Garsu Pasaulis. The money continued to flow into Plahotniuc's coffers even after he fled Moldova in June 2019 when his name was linked to the disappearance of over a billion dollars - nearly one-eighth of Moldova's GDP - from the country's biggest banks between 2012 and 2014.

Employees at the Moldovan Money Laundering Prevention and Combating Service obtained information from their colleagues in Dubai and stated that the company's majority shareholders were the Romanian citizen Ileana-Mihaela Burcea and the company Inter Gnathonize Limited.

Between October 29, 2018, and July 30, 2019, a total of seven million euros (about 7.4 million dollars) were credited into Prime Union Solutions’ UAE bank account, largely sent from Garsu Pasaulis. The money then traveled to Burcea’s private account in UAE and six other offshore companies.

In liaison with UAE and Cyprus’ authorities, Moldova’s law enforcement agencies determined that Garsu Pasaulis transferred another 19.6 million euros (20.8 million dollars) to another Cyprus offshore company, Gnathonize Limited, also connected to Burcea.

The Cypriot firm opened a bank account in July 2014, four months after Garsu Pasaulis won the Moldova tender. The Lithuanian firm was the main contributor to the account until August 2018. After that, the money was transferred to the company Prime Union INC LTD in Hong Kong and marked as a "dividend payment".

Part Two

Documents from the Hong Kong public registry show that Burcea was one of Prime Union’s shareholders and in 2014-2019 the director. In 2020, Burcea requested the closing of the company. In 2018, over 600,000 euros (639,000 dollars) were transferred from one of Prime Union’s bank accounts to another offshore in Gibraltar.

In addition, 1.5 million euros (1.6 million dollars) arrived in Burcea`s personal account in the UAE and almost 800,000 euros (852,600 dollars) were directed to Recon Business Data Service, a company registered in Dubai led by Burcea. The company was closed in December 2019.

Burcea’s lawyer Cristina Savulescu declined to comment on the financial transfers from Garsu Pasaulis to her client. She also did not comment on Burcea’s connection with Plahotniuc. Savulescu said that any association of her client with an alleged criminal case was damaging to her client's image.

"The judicial procedure in any criminal case, from the time of notification to the competent bodies until the time of sending a particular person to court, is non-public and confidential, meaning that third parties cannot know the content of the carried-out procedures," Savulescu said.

Documents obtained by Black Box with the support of the OCCRP network of investigative journalists show that Plahotniuc used the same infrastructure of offshore companies to take yet more funds out of Moldova.

The former politician used the offshore network for the money obtained from other auctions organised by state enterprises including Moldtelecom, Moldova’s largest telecommunication operator, gas supplier Energocom and the health ministry for dialysis-related services.

The UAE’s Recon Business Data Services, connected to Burcea, was also involved in the financial circuit of money leaked by Plahotniuc from another scheme related to Moldtelecom, concerning public tenders won by Bass Systems SRL in PD`s ruling period.

Between March 2017 to January 2019 the Chisinau-based IT company delivered technical equipment and services for Moldtelecom worth about 41 million euros (43.6 million dollars). Out of this amount, eight million euros (8.5 million dollars) and six million dollars followed the same route to the UAE through Recon Business Data Services.

OFFSHORE ACCOUNTS

Another document obtained from the Moldovan service for the Prevention and Combating of Money Laundering shows that the Dubai-based company made several transactions to two offshores used by Plahotniuc: the UAE-based Vanguard International LTD and Vanguard International Group, registered in Samoa.

Both companies appeared in Plahotniuc's wealth statements in 2018. However, in the document submitted to Moldova’s Central Electoral Commission on the eve of the February 24, 2019 parliamentary elections, the oligarch declared 4.5 million euros (4.78 million dollars), over 11 million lei (around 585,000 dollars) and 347,000 dollars as dividends obtained from the Dubai-based Vanguard International Ltd.

Moldovan prosecutors established the origin of the money collected by Plahotniuc as "dividends".

Vanguard International LTD received 8.2 million euros (8.72 million dollars) and 2.5 million dollars from UAE-registered RECON SPC LIMITED from December 2017 to May 2019.

Burcea and another Romanian citizen, Silviu Tutuianu, were behind the company in different periods. Almost the entire amount came from the other similarly named firm, the Dubai-based Recon Business Data Service.

Plahotniuc also collected "dividends" worth 1.7 million euros (1.80 million dollars) and almost 350,000 US dollars through another offshore company, TGME INVESTMENTS SPC LTD, managed by Tutuianu.

All these companies were liquidated between the end of 2019 and the beginning of 2020, after Plahotniuc fled Moldova. The Moldovan anti-corruption prosecutor's office opened a case for the purchase of equipment and services by Moldtelecom from SRL Bass Systems. The prosecutors confirmed that Burcea was interviewed in this criminal case, but did not disclose her status.

Burcea also managed a company that benefited from transfers from Plahotniuc’s Cyprus-registered Asia Pacific Textile Limited. This had transactions with the Cypriot offshore Melopmania Limited, the founder of BB-Dializa, a company which managed the dialysis services for the Moldovan health ministry.

BB Dializa also benefited from legal services from Cyprus-registered Kinanis offshore, founded by Burcea. The company also provided secretarial and legal services for Assentis Holdings Limited, one of the founders of Bass Systems SRL.

Asia Pacific Textile LTD received money from the Energokapital shell company. Between 2014 and 2016, the firm was used by Plahotniuc and Evgheni Shevciuk, former leader of Moldova’s breakaway region of Transnistria, to sell the electricity produced by the Russian-owned Moldgres Power Plant to Moldovan consumers.

The Black Box team tracked Energokapital's connections with Plahotniuc and the involvement of former DP deputy Vladimir Andronachi in the company's management.

Moldova’s service for the Prevention and Combating of Money Laundering established the connection between Burcea and two other offshore companies involved in looting a billion dollars from the country’s banking system: Sharp Prospects Limited and Lazomar Trading Limited, registered in Hong Kong and Cyprus respectively.

According to an international independent financial audit named the Kroll report, the Lazomar company received 5.6 million dollars in transfers to a Cypriot bank account. The Kroll report was commissioned by the National Bank of Moldova to investigate the theft that ravaged the country’s banking system.

Plahotniuc did not respond to requests for comment. His lawyer Lucian Rogac said that the former politician pleaded not guilty in the case generically called "blank passport cards".

"An indictment was presented to us. Other evidence to prove guilt was not shown by the prosecution. The only comment I can give you is that my client pleads not guilty to the charges," Rogac said.

In September 2022 Plahotniuc received an arrest warrant in absentia regarding the "blank passport cards" case, alongside Vladislav Zara, former director of the civil registry ASP, ex-PD deputy Andronachi and businessman Alexandru Vilcu. All of them have fled the country. According to Moldova’s ministry of justice, Plahotniuc is currently in Northern Cyprus.

Part Three

The scheme was taken over in the summer of 2020 by two Bulgarian companies.

In May 2020, the Lithuanian company UAB Garsu Pasaulis transferred the right for using the blank cards software to Optimo Service Ltd in Bulgaria, which ASP had co-opted to manage the documents’ personalisation programme.

"ASP proposed to have a third party take over the maintenance of the software from us. At the same time, we received proposals for cooperation from Optimo in Bulgaria," Garsu Pasaulis’ executive Andrius Lukosevicius said in a statement.

"Therefore, we wanted to avoid having any direct relationship with Optimo. While ASP persisted with its complaints [about improper maintenance of the software], we proposed to the client [ASP] that it consider entering into an agreement with Optimo (without us being involved in such a relationship) whereby Optimo would take over the software from us and its maintenance. We would no longer be responsible for this," he concluded.

Headquartered in Sofia’s luxury district of Manastirski Livadi, Optimo Service Ltd was founded on November 27, 2019, half a year before taking over the right to manage the software from Garsu Pasaulis. The founder is Russian citizen Sergey Pirojkov, while the manager is Bulgarian citizen Tsvetan Stoyanov Dimitrov.

The Bivol Investigative Journalism Centre reporter in Bulgaria, one of Black Box's partners in this investigation, went to the company's headquarters to talk to the owners. According to the documents detailing the company’s address, the offices are on the top floor of a residential building, where a beauty salon is also located. There is no plaque indicating the presence in this location of businesses involving ASP and Garsu Pasaulis.

In November 2022, a Bivol reporter knocked on the door. An employee of the beauty salon opened it and said that at the end of the corridor there was an office where "two Russian guys are working on computers, Serioja and Anton". The two men "rarely come to work".

On October 26, 2020, Optimo Service transferred its commitments to ASP to another Bulgarian company, Optimo IT Solutions LTD, whose owner is none other than Stoyanov, Optimo Service’s manager.

Two weeks before this deal, Stoyanov bought an older company and changed its name to Optimo IT Solutions.

Almost two months after Stoianov’s take over, the ASP funds began to flow into the accounts of Optimo IT Solutions as royalty fees for delivering the IDs and passports

According to documents seen by the Black Box team, between November 24, 2020, and August 13, 2021, ASP made 19 payments totaling 5.6 million euros (5.96 million dollars), to the newly established Optimo IT Solutions LTD.

The director of ASP, Mircea Esanu, told Black Box about the shady software rights transfer to Bulgarian companies.

"I assume who is [the beneficiary of those companies]. I have yet to see documents demonstrating where the money went from those accounts of the Bulgarian companies. But for me, it is strange when a company, even a printing house, sells practically for free to a Bulgarian company created overnight and later collects 5.6 million euros (5.96 million dollars) for a year,” he said.

On the same day in November 2022, the Bivol reporter returned to Optimo IT Solutions’ offices in central Sofia, to talk to the company's owner. The office is in an old building and access to the courtyard is prohibited. Employees of the company providing the space for rent refused to grant allow the reporter inside the building. The accountant of the same company refused to give any details.

Black Box called Optimo IT Solutions headquarters to talk to Stoyanov. The company secretary said to send questions by e-mail, but reporters did not receive an answer.

NEW MANAGEMENT

Returning to the summer of 2020, Optimo Service took over the royalty scheme. One month after transferring the rights to the document personalisation software, the Bulgarian company decided to take a Moldovan partner to represent its interests with ASP.

The company wrote to ASP that IT-LAB GRUP SRL would manage the software. The connections led to the Moldovan businessman Alexandru Vilcu.

According to the letter sent to the ASP by the Bulgarian company, IT-LAB GRUP was to deal not only with the technical servicing of the software but to also manage the entire business administration process.

Furthermore, the Moldovan business would be allowed to hold the Optimo Service company stamp, sign documents, and receive and make payments on behalf of the Bulgarian enterprise.

In November 2022, the founder of IT-LAB GRUP, Alexey Cioban, told Black Box that he did not provide any services to ASP because he no longer cooperated with the Bulgarian company. He claims that he was contacted directly from Sofia but did not say with whom he negotiated.

"We had some discussions about a potential partnership. I also went to ASP, and we discussed concluding a contract, but [we did not], with neither ASP nor the Bulgarian company. We did not reach an agreement. We didn't do any work. We didn't get any money and wanted to avoid collaborating with this company [Optimo],” Cioban said. "We had to take care of the technical part, the software, and the equipment installed at ASP. I talked with ASP, found out more details, and said it differs from our line of work. We refused."

Documents however show that the partnership between Optimo Service and IT-LAB lasted half a year and their collaboration contract was terminated in January 2021.

Cioban's firm, delegated by the Bulgarians to defend their interests in Moldova, has its legal address in Chisinau’s Rascani neighbourhood. According to the land registry, the building in which IT-LAB operates belongs to Tehnovin, a machinery manufacturing company owned by Vilcu.

Cioban categorically denied he ever collaborated with Vilcu in the business of Moldova’s public service agency.

In an exchange of messages with Black Box, Vilcu admitted that he tried to arrange a partnership with the company from Bulgaria and proposed a collaboration with IT-LAB. This contradicts Cioban, who denied his partner's involvement in the ASP case.

"We tried with Alexei [Cioban] to partner with those from Lithuania, but after an analysis, Alexei understood that he would not be able to cope with this and refused. And there, believe me, there was no mention of the figures I read in the files and the press,” Vilcu said.

He added it was a "decent proposal for Moldova," about "tens of thousands, not millions".

In September 2020, Vilcu received an arrest warrant in absentia; he did not appear at the hearing as requested by prosecutors.

Vilcu denies allegations that he was one of the beneficiaries of the ASP scheme and claims he initiated his own investigation to find out who benefited from the money stolen from the passports.

"I want to assure you that I did not participate in this affair. I had nothing to do with passports or other documents from Moldova. I have never dealt with a business that is outside the law. I was less interested in the Bulgarian company. I was more interested in the documents based on which the criminal file was opened against me," Vilcu said.

MULTIPLE CONNECTIONS

Another character targeted in the passport blanks case was the former deputy Vladimir Andronachi.

The anti-corruption prosecutor's office has established connections between the Bulgarian companies Optimo Service and Optimo IT Solutions with Andronachi and relationships with businessman Alexandru Vilcu.

The prosecutor's office stated that it is verifying Andronachi and Vilcu’s involvement in the ASP scheme.

“We inform you that a preliminary link of connection has been established between these natural and legal persons, but the criminal prosecution body still verifies the factual circumstances of these links. In this sense, requests for rogatory commissions are to be formulated," the statement read.

An official source said that the connection between Andronachi and the companies in Bulgaria was ensured by his family’s lawyer, Carolina Andriuta, who allegedly managed the Bulgarian companies from Chisinau. Black Box reporters have not been able to independently verify these allegations.

The anti-corruption prosecutor's office confirmed that Andriuta is accused in the criminal case “for complicity in the abuse of office and money laundering” but stated that the investigation continues.

Andriuta managed several companies connected to Andronachi. Currently, she is on the accused bench in a case concerning bank fraud, together with Nadejda Andronachi, Vladimir Andronachi’s wife.

Oleg Mita, Vladimir Andronachi’s lawyer, who was recently detained in Ukraine and extradited to Moldova on November 2, 2022 did not respond to questions.

Andronachi remains in prison and Mita states that he pleads not guilty in the “passport affairs” case.

"Mr Andronachi had been officially charged in this case. But he does not admit his fault. He explained to the prosecutors that he knew nothing about such actions related to so-called passport forgery schemes," the lawyer said.

Mita is also Carolina Andriuta's lawyer. Mita claims that Andriuta was not accused and also pleaded not guilty.

Melvin Kramer

[aishavass]

In 2018, North America dominated the global hemodialysis and peritoneal dialysis market by contributing over 36% and is anticipated to maintain its market...

[bhushans]

Global Focus on Improved Outcomes: Global Hemodialysis and Peritoneal Dialysis Market

The global hemodialysis and peritoneal dialysis markets is ready to change and have a lasting influence that lasts well into 2034 and beyond. Hemodialysis and peritoneal dialysis are expected to cost a combined USD 104.3 billion by 2024. The market is anticipated to be worth more than USD 245 billion by 2034.

Hemodialysis and peritoneal dialysis are predicted to grow at a strong 8.9% CAGR until 2034.

Enhance Research With a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14681

Key Highlights:

Strong Regulatory Framework and Healthcare Infrastructure: North America’s hemodialysis and peritoneal dialysis market is benefiting from the region’s stringent regulatory standards and advanced healthcare infrastructure. Regulatory compliance ensures patient safety and quality of care, while state-of-the-art facilities and technologies facilitate the delivery of effective dialysis treatments.

Rising Prevalence of Renal Diseases: The increasing prevalence of renal diseases, including chronic kidney disease (CKD) and end-stage renal disease (ESRD), is driving the demand for hemodialysis and peritoneal dialysis treatments. Factors such as aging populations, lifestyle-related risk factors, and improved diagnostic capabilities contribute to the growing burden of renal conditions, necessitating expanded dialysis services.

Technological Advancements and Innovation: Technological advancements in hemodialysis and peritoneal dialysis modalities are enhancing treatment efficacy, patient comfort, and convenience. Innovations such as wearable dialysis devices, home-based dialysis solutions, and remote monitoring systems are reshaping the dialysis landscape, empowering patients to manage their condition more effectively and improve their quality of life.

Focus on Personalized and Value-Based Care: The shift towards personalized and value-based care models is driving the adoption of tailored dialysis regimens that optimize patient outcomes and resource utilization. Integrated care approaches, multidisciplinary care teams, and patient-centered initiatives aim to address the holistic needs of individuals with renal diseases, promoting better health outcomes and cost-effective care delivery.

Key Takeaways : 

In the type sector, Hemodialys from the Hemodialys and peritoneal dialysis market are anticipated to flourish at the quickest CAGR of 5.5% through 2032.

With a CAGR of 5.7% through 2032, Hospital Dialysis are predicted to grow significantly in the application sector of the Hemodialys and peritoneal dialysis market.

The market size for Hemodialys and peritoneal dialysis market in the United States is expected to reach US$ 49.4 Billion by 2032, growing at a CAGR of 6% during the research period.

China is anticipated to reach a market size of US$ 10.2 billion in Hemodialys and peritoneal dialysis by 2032, with a CAGR of 5.5% during the forecast period.

By 2032, South Korea is expected to reach a market size of US$ 5.3 Billion in Hemodialys and peritoneal dialysis, with a CAGR of 49% during the forecast period.

COMPETITIVE LANDSCAPE: 

The major players in the global hemodialys and peritoneal dialysis market are Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International, Inc. (US), Nikkiso Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Asahi Kasei Corporation (Japan), DaVita Inc. (US), Nipro Corporation (Japan), Cantel Medical Corporation (US), Diaver (US).

RECENT DEVELOPMENT: 

Mar Cor (Cantel Medical Corporation) announced the release of their unique EON Portable Hemodialys Water System in 2021.

Fresenius Medical Care AG & Co. KGaA announced the release of a PVC-free peritoneal dialysis solution bag for home dialysis therapy in 2020.

Baxter International Inc. gained FDA clearance for a De Novo application for Theranova dilayzers designed to provide enhanced hemodialys (HDx) treatment in 2020.

KEY SEGMENTS:

By Type:

Hemodialys

Peritoneal dialysis

By End Use:

Hospital Based

By Product:

Device

Consumables

Services

By Region:

North America

Latin America

Europe

Asia Pacific

Middle East & Africa

[markettrendsus]

Kidney Dialysis Market: Size, Share, Growth and Forecast 2032

The Global Kidney Dialysis Market is expected to reach a value of USD 83.4 billion in 2023, and it is further anticipated to reach a market value of USD 143.8 billion by 2032 at a CAGR of 6.2%. Kidney dialysis is a procedure used to remove waste and excess fluid from the blood when the kidneys are unable to perform this function properly. The increasing prevalence of chronic kidney diseases, rising healthcare expenditures, technological advancements in dialysis products and growing geriatric population are major factors driving the growth of the kidney dialysis market.

Drivers of the Kidney Dialysis Market

The rising incidence of kidney diseases is a major driver for the kidney dialysis market. Diabetes and hypertension are the leading causes of kidney disease. With rising rates of obesity and diabetes, more people are developing chronic kidney diseases. According to the Centers for Disease Control and Prevention (CDC), 15% of US adults are estimated to have chronic kidney disease.

The growing geriatric population is another key driver for the market. Older people are more prone to acute and chronic kidney diseases. The UN estimates that the global population aged 60 years or over will grow by 56% between 2020 and 2030. This expanding pool of geriatric population will drive the demand for dialysis.

Technological advancements and new product launches by leading players are also fueling the growth of the kidney dialysis market. Companies are focusing on developing advanced dialysis machines and dialyzers to improve efficiency and patient outcomes. The integration of connected technologies such as remote monitoring is also driving market growth.

Request For Sample: https://www.dimensionmarketresearch.com/report/kidney-dialysis-market/requestSample.aspx

Segments of the Kidney Dialysis Market

Hemodialysis Segment

The hemodialysis segment held the largest share of the market in 2022. Hemodialysis is the most common modality used by patients with chronic kidney disease. The rising incidence of End Stage Renal Disease (ESRD), favorable reimbursement policies, and availability of advanced hemodialysis products are driving this segment.

Peritoneal Dialysis Segment

Peritoneal dialysis is projected to register the highest CAGR during the forecast period. It offers greater flexibility to patients in terms of lifestyle and traveling. Technological developments in cyclers and connectology are also fueling the adoption of peritoneal dialysis.

In-center Dialysis Segment

In-center dialysis dominated the market in 2022 in terms of service providers. In-center dialysis provides monitoring by skilled staff during the entire treatment. The segment is driven by favorable reimbursement policies and the expanding network of dialysis centers globally.

Home Dialysis Segment

The home dialysis segment is expected to expand at the highest rate over the forecast period. Home dialysis offers increased flexibility and independence to patients. Rising awareness of home dialysis and introduction of innovative products by key players are propelling the growth of this segment.

Request For Sample: https://www.dimensionmarketresearch.com/report/kidney-dialysis-market/requestSample.aspx

Regional Analysis

North America accounted for the largest share of the global kidney dialysis market in 2022. High incidence of ESRD, established healthcare infrastructure, rising healthcare spending and presence of key players are driving the North America kidney dialysis market.

Asia Pacific is anticipated to grow at the fastest rate during the forecast period owing to the rising prevalence of diabetes & hypertension, increasing healthcare expenditure and expanding geriatric population in the region.

Key Players

Some major companies operating in the global kidney dialysis market include:

- Fresenius Medical Care - Baxter International Inc. - Nipro Corporation - B. Braun Melsungen AG - Nikkiso Co., Ltd - Becton, Dickinson and Company - Medtronic Plc - Asahi Kasei Corporation - Terumo Corporation - Renal Technologies Limited

These players are adopting strategies such as new product launches, mergers & acquisitions and geographical expansions to increase their share in the kidney dialysis market.

Future Outlook

The global kidney dialysis market is projected to continue its robust growth during the forecast period. The market will be driven by the rising burden of chronic kidney diseases, favorable government initiatives to increase access to dialysis, technological innovations and increasing geriatric population. Emerging markets in Asia Pacific and Latin America also present significant opportunities due to improving healthcare infrastructure.

However, the high cost of dialysis products and services limits access in developing regions. Stringent regulatory scenario also poses a challenge to market growth. Leading players operating in the market are investing in R&D to develop advanced and flexible dialysis systems to improve clinical outcomes and quality of life for patients. The future outlook for the kidney dialysis market remains positive driven by the rising patient population and technology progress.

Request For Sample: https://www.dimensionmarketresearch.com/report/kidney-dialysis-market/requestSample.aspx

Frequently Asked Questions

Q1: What is the global kidney dialysis market size?

A1: The global kidney dialysis market size was valued at $89.2 billion in 2022 and is projected to reach $136.1 billion by 2030.

Q2: What is driving the kidney dialysis market growth?

A2: Key factors driving kidney dialysis market growth include rising incidence of chronic kidney diseases, growing geriatric population, technological advancements in dialysis products and favorable government initiatives.

Q3: Which region dominates the kidney dialysis market?

A3: North America accounted for the largest share of the global kidney dialysis market in 2022. Rising prevalence of End Stage Renal Disease (ESRD), established healthcare infrastructure and presence of key players drive the North America market.

Q4: Who are the key players in the kidney dialysis market?

A4: Leading companies in the kidney dialysis market include Fresenius Medical Care, Baxter International Inc., Nipro Corporation, B. Braun Melsungen AG, Nikkiso Co. Ltd., among others.

Q5: Which is the fastest growing segment in the kidney dialysis market?

A5: The peritoneal dialysis segment is projected to register the highest CAGR during the forecast period owing to flexibility, technological advancements in cyclers and connectology.

Q6: What is the future outlook for the kidney dialysis market?

A6: The global kidney dialysis market is projected to grow at a CAGR of 4.9% from 2023 to 2030, driven by rising burden of kidney diseases, favorable government policies, new product launches and increasing access to dialysis services globally.

Conclusion

The kidney dialysis market is poised for steady growth in the coming years driven by the rising incidence of chronic kidney diseases worldwide, expanding geriatric population, advancements in dialysis technologies and increasing healthcare expenditure. Key players are focusing on developing innovative dialysis systems and expanding their geographic presence to tap growth opportunities.

The rising adoption of home dialysis presents a significant opportunity for manufacturers. At the same time, high costs of dialysis remain a challenge, especially in developing regions. Going forward, increasing awareness programs, favorable reimbursements and government funding initiatives will help increase access to dialysis therapy for patients worldwide. Market players need to focus on emerging economies which present immense growth potential owing to the large patient base and improving healthcare infrastructure.

[hiranandanihospitalpowai]

The benefits of getting kidney care at Dr L H Hiranandani Hospital

Hiranandani Hospital is a multi-specialty healthcare center based in Powai, Mumbai. Dr L H Hiranandani is the learned soul behind this brilliant healthcare project. And today, the hospital is serving influentially in the metro city with more than 240 operational beds.

Dr Sujit Chatterjee, CEO - Dr L H Hiranandani Hospital says, that he is dedicatedly working on bringing the best facilities and quality care related to kidney diseases and kidney failure in the department. His good work is carried with concern, and respect for every patient which is the support system of this entire hospital. The hospital is actively associated with the mission to deliver the best quality and affordable healthcare services to the citizens of India through skilled doctors and an interactive business model. In aggregate, the hospital provides advanced levels of care in more than 20 specialties, including cancer care, orthopedics, human reproduction, bariatric surgery, nephrology, critical care, cardiology, gynecology, physical rehabilitation, neurology and others.

Dr L H Hiranandani Powai Hospital is a renowned multispecialty hospital in Mumbai, India, that offers a wide range of medical services, including kidney treatment. Here are some reasons why it is the best place to get kidney treatment:

•  It has a dedicated Centre for Renal Sciences that provides comprehensive care for patients with kidney diseases and disorders. The center offers advanced diagnostic and therapeutic facilities, such as kidney biopsy, dialysis, peritoneal dialysis, hemodialysis, continuous renal replacement therapy (CRRT), and kidney transplantation.

•  It has a team of highly qualified and experienced nephrologists, urologists, transplant surgeons, anesthetists, nurses, and technicians who work together to provide the best possible care for the patients. The team follows international standards and protocols to ensure quality and safety.

•  It has a state-of-the-art kidney transplant unit that performs both live and cadaveric donor kidney transplants. The unit has a dedicated transplant ICU with modern equipment and facilities to monitor and treat the patients after the surgery. The unit also has a transplant coordinator who guides and counsels the patients and their families throughout the process.

•  It has a patient-centric approach that focuses on providing holistic care for the patients and their families. The hospital offers various services and amenities to make the patients comfortable and satisfied, such as 24/7 emergency services, online appointments, health check-ups, health insurance, pharmacy, cafeteria, library, prayer room, and free Wi-Fi.

•  It has received several awards and accolades for its excellence in kidney treatment, such as the Best Hospital for Nephrology in India by Times Health Survey 2020, the Best Hospital for Renal Transplant in India by India Healthcare Awards 2019, and the Best Hospital for Nephrology in Mumbai by Times Health Survey 2019.

[research--blog]

Home Healthcare Market to be Worth $514.5 Billion by 2030 - Exclusive Report by Meticulous Research®

 According to a new market research report titled, ‘Home Healthcare Market by Offering (Fertility, Pregnancy, Cholesterol Tests, Oxygen Delivery, Dialysis, IV, Patient Support Equipment), Services (Rehabilitation, Telehealth, Nursing, Hospice), Application (Cardiovascular, Diabetes)- Global Forecast to 2030,’ published by Meticulous Research®, the home healthcare market is projected to reach $514.5 billion by 2030, at a CAGR of 7.9% from 2023 to 2030.

Population aging is the dominant demographic trend of the twenty-first century—a reflection of increasing longevity, declining fertility, and the progression of a large number of individuals to older ages. The OECD forecasts that, globally, the population aged 60 and over is expected to reach 2.1 billion by 2050. As per the World Health Organization (WHO) statistics, the global population in the age group of 60 years and above was expected to increase from 1 billion in 2020 to 1.4 billion in 2022. The growth in the aging population has resulted in the increased adoption of home healthcare services due to the high costs of hospital healthcare services.

Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=1280

The geriatric population is highly susceptible to diseases such as high blood pressure, diabetes, arthritis, and cardiovascular diseases. Therefore, the growing global geriatric population, coupled with the fact that approximately 70% of home health patients belong to the age group of 65 years and above, is expected to drive the demand for home healthcare products and services during the forecast period.

Impact of COVID-19 on the Home Healthcare Market

The COVID-19 pandemic positively impacted the home healthcare market. The pandemic has increased the preference for home healthcare due to the risks of acquiring infections during hospital and clinic visits for treatment and related purposes. The pandemic has also increased the adoption of telehealth, making it a primary source of care for many patients. According to the 2021 World Economic Forum’s 5G Outlook Series report, there has been an increase of 490% in telemedicine visits for urgent cases. Furthermore, the outbreak of the COVID-19 pandemic increased the demand for home healthcare infrastructure and increased investments from governments in promoting homecare services. For instance, in August 2022, Fresenius Medical Care North America, the North American division of Fresenius Medical Care AG & Co. KGaA (Germany), acquired Interwell Health U.S. This acquisition was aimed at bringing Fresenius Health Partners’ expertise in kidney care and value-based performance and contracting.

The home healthcare market is segmented based on Offering (Home Tests and Patient Monitoring Equipment [Fertility Tests & Aids, Pregnancy Tests, Gender, DNA, and Parental Tests, Cholesterol Tests, HIV Tests, Holter Monitors, Blood Pressure Monitors, Oximeters, Heart Rate Monitors,

Thermometers, Stethoscopes, Defibrillators, Pedometers, Scales & Body Fat Monitors, Peak Flow Meters, Apnea Monitors, Baby Monitors, Coagulation Monitors, Diabetes Management]), Home Therapeutic Equipment ({Home Respiratory Therapy Equipment, [Continuous Positive Airway Pressure Equipment (CPAP Machines, CPAP Accessories & Consumables)], Oxygen Delivery Equipment, Nebulizers & Accessories, Ventilators & Accessories}, Home Dialysis Equipment, {Home Peritoneal Dialysis Products, Home Hemodialysis Products}, Home IV Equipment {IV Pumps, Other Home IV Equipment}, Other Equipment), Patient Support Equipment, {Mobility Assist Equipment, [Wheelchairs], Walking Assist Devices {Walking Assist Devices, [Walkers and Rollators, Canes & Walking Sticks, Crutches], Mobility Scooters, Medical Furniture and Accessories, Bathroom Safety Equipment), Services (Rehabilitation Services, Infusion Services, Skilled Care/Nursing, Unskilled Care Services, Telehealth Services, Hospice Care Services, Respiratory Therapy Services, Other Services), Application (Cardiovascular Diseases & Hypertension, Diabetes, Respiratory Diseases, Pregnancy, Mobility Disorders, Cancer, Wound Care, and Other Applications) and Geography. The study also evaluates industry competitors and analyzes their market shares at the country and regional levels.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business : https://www.meticulousresearch.com/speak-to-analyst/cp_id=1280

Based on offering, in 2023, the home therapeutic equipment segment is expected to account for the largest share of the home healthcare market. The growth of this segment is attributed to increasing cases of chronic kidney and respiratory diseases, the high costs of therapeutic services in hospitals, and the availability of rental products, including ventilators, nebulizers, and oxygen delivery equipment.

Based on services, the skilled care/nursing segment is projected to register the highest CAGR during the forecast period. The growth of this segment is attributed to the wide range of daily tasks performed by nurses to provide adequate care for patients receiving homecare, the rising adoption of home-based treatments that require technical knowledge of operating healthcare products which includes home dialysis equipment, and home IV equipment, home respiratory therapy equipment, and the increasing demand for home care for the elderly population.

Based on application, in 2023, the diabetes segment is expected to account for the largest share of the home healthcare market. The growth of this segment is attributed to the rising number of diabetic patients globally who are more prone to diseases such as cardiovascular diseases and Alzheimer's disease. Furthermore, the growing need to monitor the heart rate, hemoglobin, cholesterol, and blood pressure levels of diabetic patients contributes to the growth of this market segment.

“Exciting news! We are thrilled to announce an incredible opportunity for you!

For a limited time only, we are delighted to offer an exclusive flat 30% discount on all our remarkable research reports. It's our way of showing appreciation for your continuous support and commitment to staying informed. This remarkable discount allows you to unlock a wealth of valuable insights and expert analysis at an unbeatable price. Whether you're a business professional, an academic researcher, or an avid learner, this offer is tailor-made to enhance your knowledge and empower your decision-making.”

Quick Buy – Home Healthcare Market - Global Opportunity Analysis And Industry Forecast (2023-2030), Research Report: https://www.meticulousresearch.com/Checkout/85264114

Based on geography, in 2023, North America is expected to account for the largest share of the home healthcare market, followed by Europe and Asia-Pacific. Furthermore, in 2023, the U.S. is expected to be the largest shareholding market in North America. The market growth in the U.S. is attributed to the high disposable incomes of the population, the rising number of patients with chronic diseases, and government investments in promoting home healthcare.  However, Asia-Pacific is expected to witness a rapid growth during forecast period. The growth of this regional market is attributed to the increasing geriatric population, the rising prevalence of chronic diseases in developing nations, the increasing investments in home healthcare in developing countries such as China and India, and the higher preference for home-based treatments due to the high costs of hospital services. Furthermore, government initiatives promoting homecare and the launch of advanced homecare products are driving the growth of the home healthcare market in Asia-Pacific.

The report also includes an extensive assessment of the key growth strategies adopted by leading market players in the past three to four years. In the last couple of years, the home healthcare market has witnessed various developments.

Some of the key players operating in the home healthcare market are Abbott Laboratories (U.S.), Amedisys, Inc (U.S.), Owens & Minor (U.S.), B. Braun SE (Germany), Baxter International, Inc. (U.S.), BAYADA Home Health Care (U.S.), Convatec (U.K.), Halyard Health, Inc. (U.S.), Covidien (Ireland), Fisher & Paykel (New Zealand), Fresenius Medical (Germany), GE Healthcare (U.S.), Johnson & Johnson (U.S.), and F. Hoffmann-La Roche AG (Switzerland).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/home-healthcare-market-1280

Scope of the Report:

Home Healthcare Market, by Offering

Home Tests and Patient Monitoring Equipment

Fertility Tests & Aids

Pregnancy Tests

Gender, DNA, and Parental Tests

Cholesterol Tests

HIV Tests

Holter Monitors

Blood Pressure Monitors

Oximeters

Heart Rate Monitors

Thermometers

Stethoscopes

Defibrillators

Pedometers

Scales & Body Fat Monitors

Peak Flow Meters

Apnea Monitors

Baby Monitors

Coagulation Monitors

Diabetes Management               

Home Therapeutic Equipment

Home Respiratory Therapy Equipment

Continuous Positive Airway Pressure Equipment

CPAP Machines

CPAP Accessories & Consumables

Oxygen Delivery Equipment

Nebulizers & Accessories

Ventilators & Accessories

Home Dialysis Equipment

Home Peritoneal Dialysis Products

Home Hemodialysis Products

Home IV Equipment

IV Pumps

Other Home IV Equipment

Other Equipment

Patient Support Equipment

Mobility Assist Equipment

Wheelchairs

Walking Assist Devices

Walkers and Rollators

Canes & Walking Sticks

Crutches

Mobility Scooters

Medical Furniture and Accessories

Bathroom Safety Equipment

Home Healthcare Market, by Services

Rehabilitation Services

Infusion Services

Skilled Care / Nursing

Unskilled Care Services

Telehealth Services

Hospice Care Services

Respiratory Therapy Services

Other Services

Home Healthcare Market, by Application

Cardiovascular Diseases & Hypertension

Diabetes

Respiratory Diseases

Pregnancy

Mobility Disorders

Cancer

Wound Care

Other Applications

Home Healthcare Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

Italy

U.K.

Spain

Rest of Europe (RoE)

Asia-Pacific

China

Japan

India

Rest of Asia-Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Download Free Report Sample Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=1280

[missionarynurse]

I’m Nurse Assistant at Medical Center Taguig.

Assigned at Medical-Surgical Ward and Emergency Room. 

Rotated at Hemodialysis Unit and Operating Room. 

(November 2019 - July 2020) 

Main Reason why I allowed myself to be NA while my other classmates are already RN? 

“sobrang sakit na wala pa akong pambayad ng tuition fee balance ko. 

sobrang sakit na hindi ko naipasa ang course audit in my last year of nursing school.”

but I continued achingly, 

I still dream anyway.

I look forward to be the Head of Nursing Division someday.

I want to be in the grass roots. 

I want to be involved with the unnoticed workers of the hospital.

I still love anyway.

I still care anyway.

https://www.instagram.com/stories/highlights/17895169744409900/